Title : Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

Pub. Date : 2013 May

PMID : 23468082






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. ponatinib mechanistic target of rapamycin kinase Homo sapiens
2 CONCLUSIONS: These encouraging preclinical findings suggest the inhibition of both FGFR2 and mTOR by the ponatinib-ridaforolimus combination may provide a new therapeutic strategy to treat advanced endometrial cancers with dual pathway dysregulation. ponatinib mechanistic target of rapamycin kinase Homo sapiens